Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Operating Income (2022 - 2026)

Axsome Therapeutics' Operating Income history spans 5 years, with the latest figure at -$63.4 million for Q1 2026.

  • On a quarterly basis, Operating Income fell 11.19% to -$63.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$44.9 million, a 83.4% increase, with the full-year FY2025 number at -$38.5 million, up 86.29% from a year prior.
  • Operating Income hit -$63.4 million in Q1 2026 for Axsome Therapeutics, down from $101.3 million in the prior quarter.
  • Over the last five years, Operating Income for AXSM hit a ceiling of $101.3 million in Q4 2025 and a floor of -$98.3 million in Q4 2023.
  • Historically, Operating Income has averaged -$46.7 million across 5 years, with a median of -$59.9 million in 2022.
  • Biggest five-year swings in Operating Income: plummeted 955.46% in 2024 and later surged 239.53% in 2025.
  • Tracing AXSM's Operating Income over 5 years: stood at -$59.9 million in 2022, then tumbled by 64.01% to -$98.3 million in 2023, then rose by 26.11% to -$72.6 million in 2024, then surged by 239.53% to $101.3 million in 2025, then tumbled by 162.53% to -$63.4 million in 2026.
  • Business Quant data shows Operating Income for AXSM at -$63.4 million in Q1 2026, $101.3 million in Q4 2025, and -$46.1 million in Q3 2025.